Ashfield Capital Partners’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $25.6M | Sell |
50,517
-449
| -0.9% | -$251K | 2.15% | 7 |
|
|
2022
Q2 | $27.7M | Buy |
50,966
+1,974
| +4% | +$1.09M | 2.15% | 7 |
|
|
2022
Q1 | $28.9M | Buy |
48,992
+3,979
| +9% | +$2.29M | 1.87% | 11 |
|
|
2021
Q4 | $30M | Sell |
45,013
-107
| -0.2% | -$66.8K | 1.93% | 10 |
|
|
2021
Q3 | $25.8M | Buy |
45,120
+30
| +0.1% | +$16.5K | 1.84% | 12 |
|
|
2021
Q2 | $22.7M | Sell |
45,090
-137
| -0.3% | -$64.6K | 1.62% | 13 |
|
|
2021
Q1 | $20.6M | Sell |
45,227
-1,412
| -3% | -$674K | 1.64% | 14 |
|
|
2020
Q4 | $21.7M | Buy |
46,639
+120
| +0.3% | +$56.3K | 1.76% | 11 |
|
|
2020
Q3 | $20.5M | Buy |
46,519
+2,760
| +6% | +$1.14M | 1.86% | 11 |
|
|
2020
Q2 | $15.9M | Buy |
43,759
+216
| +0.5% | +$72.4K | 1.57% | 17 |
|
|
2020
Q1 | $12.3M | Sell |
43,543
-1,062
| -2% | -$335K | 1.5% | 19 |
|
|
2019
Q4 | $14.5M | Sell |
44,605
-151
| -0.3% | -$45.8K | 1.44% | 21 |
|
|
2019
Q3 | $13M | Buy |
44,756
+901
| +2% | +$258K | 1.41% | 22 |
|
|
2019
Q2 | $12.9M | Buy |
43,855
+196
| +0.4% | +$54K | 1.37% | 23 |
|
|
2019
Q1 | $11.9M | Buy |
43,659
+992
| +2% | +$247K | 1.31% | 22 |
|
|
2018
Q4 | $9.55M | Buy |
42,667
+832
| +2% | +$195K | 1.24% | 27 |
|
|
2018
Q3 | $10.2M | Sell |
41,835
-954
| -2% | -$219K | 1.14% | 28 |
|
|
2018
Q2 | $8.86M | Sell |
42,789
-984
| -2% | -$209K | 1.11% | 26 |
|
|
2018
Q1 | $9.04M | Sell |
43,773
-1,223
| -3% | -$257K | 1.18% | 23 |
|
|
2017
Q4 | $8.54M | Sell |
44,996
-260
| -0.6% | -$49.8K | 1.1% | 26 |
|
|
2017
Q3 | $8.56M | Sell |
45,256
-1,934
| -4% | -$350K | 1.15% | 25 |
|
|
2017
Q2 | $8.23M | Buy |
47,190
+399
| +0.9% | +$67K | 1.13% | 26 |
|
|
2017
Q1 | $7.19M | Sell |
46,791
-46,734
| -50% | -$7.14M | 1% | 31 |
|
|
2016
Q4 | $13.2M | Sell |
93,525
-23,731
| -20% | -$3.5M | 1.29% | 21 |
|
|
2016
Q3 | $18.7M | Sell |
117,256
-11,418
| -9% | -$1.76M | 1.54% | 15 |
|
|
2016
Q2 | $19M | Sell |
128,674
-24,761
| -16% | -$3.65M | 1.53% | 20 |
|
|
2016
Q1 | $21.7M | Buy |
153,435
+43,282
| +39% | +$5.8M | 1.57% | 18 |
|
|
2015
Q4 | $15.6M | Sell |
110,153
-95,418
| -46% | -$12.7M | 1.07% | 32 |
|
|
2015
Q3 | $25.1M | Sell |
205,571
-16,207
| -7% | -$2.11M | 1.61% | 18 |
|
|
2015
Q2 | $28.8M | Sell |
221,778
-6,540
| -3% | -$853K | 1.58% | 18 |
|
|
2015
Q1 | $30.7M | Sell |
228,318
-44,329
| -16% | -$5.71M | 1.63% | 16 |
|
|
2014
Q4 | $34.2M | Sell |
272,647
-4,891
| -2% | -$595K | 1.65% | 15 |
|
|
2014
Q3 | $33.8M | Sell |
277,538
-8,146
| -3% | -$990K | 1.64% | 17 |
|
|
2014
Q2 | $33.7M | Sell |
285,684
-7,872
| -3% | -$926K | 1.59% | 18 |
|
|
2014
Q1 | $35.3M | Sell |
293,556
-8,945
| -3% | -$1.06M | 1.7% | 18 |
|
|
2013
Q4 | $33.7M | Sell |
302,501
-6,295
| -2% | -$626K | 1.61% | 16 |
|
|
2013
Q3 | $28.5M | Sell |
308,796
-16,295
| -5% | -$1.47M | 1.47% | 24 |
|
|
2013
Q2 | $27.5M | Buy |
+325,091
| New | +$27.1M | 1.48% | 20 |
|
Other funds holding TMO
Ashfield Capital Partners's TMO Position: Q3 2022 in Review
Ashfield Capital Partners reduced its Thermo Fisher Scientific (TMO) stake by 0.88% in Q3 2022, selling an estimated $251K and leaving 50,517 shares worth $25.6M. The position accounts for 2.15% of the portfolio, ranked #7.
Ashfield Capital Partners first reported a position in TMO in Q2 2013 and has held it in 38 quarters since. The position peaked at $35.3M in Q1 2014. 2,266 funds tracked by Wall St. Rank hold TMO as of Q3 2022.
- Ashfield Capital Partners held 50,517 shares of Thermo Fisher Scientific worth $25.6M as of Q3 2022.
- Ashfield Capital Partners sold 449 Thermo Fisher Scientific shares in Q3 2022, an estimated $251K.
- Thermo Fisher Scientific made up 2.15% of Ashfield Capital Partners's portfolio in Q3 2022, its #7 holding.
- Ashfield Capital Partners first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 38 quarters since.
- Ashfield Capital Partners's Thermo Fisher Scientific position peaked at $35.3M in Q1 2014.
- 2,266 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2022.
Based on Ashfield Capital Partners's 13F filing for Q3 2022, filed 10 Nov 2022.